Compare ENTX & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | GRX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 147.2M |
| IPO Year | 2018 | N/A |
| Metric | ENTX | GRX |
|---|---|---|
| Price | $2.16 | $9.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 82.8K | 39.7K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.98% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $124,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.50 |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.50 | $7.73 |
| 52 Week High | $3.22 | $10.40 |
| Indicator | ENTX | GRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 57.61 |
| Support Level | $2.05 | $9.47 |
| Resistance Level | $2.53 | $9.71 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 13.42 | 62.71 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.